Author

M. Sanhaji

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

A. C. Joerger· 2 shared A. Poso· 2 shared K. Strebhardt· 2 shared L. M. Berger· 2 shared M. Raab· 2 shared M. Rak· 2 shared R. Tesch· 2 shared S. Knapp· 2 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. C. Joerger

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistryEuropean Journal of Medicinal ChemistryPeer-reviewedJun 1, 2023

Shifting the selectivity of pyridopyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily

M. Rak, R. Tesch, L. M. Berger…·S. Knapp

This paper develops a selective SIK kinase inhibitor, MR22, by optimizing a pyrido[2,3-d]pyrimidin-7(8H)-one scaffold to eliminate PAK activity, demonstrating its efficacy in ovarian cancer cells.

DOI 10.1016/j.ejmech.2023.115347

humanproteomics

𝕏 PostBluesky

BiochemistrybioRxivPreprintApr 8, 2021

Structure-based design of selective salt-inducible kinase (SIK) inhibitors

R. Tesch, M. Rak, M. Raab…·S. Knapp

This study designs a selective SIK inhibitor, MRIA9, based on a PAK inhibitor, showing its dual activity and potential for combination therapy in ovarian cancer.

DOI 10.1101/2021.04.08.439011

humanproteomics

𝕏 PostBluesky